Recent perspectives on the virulent factors and treatment options for multidrug-resistant Acinetobacter baumannii

References

• Ahmad S, Shaker B, Ahmad F, Raza S, Azam SS. 2018. Moleculer dynamics simulaiton revealed reciever domain of Acinetobacter baumannii BfmR enzyme as the hot spot for future antibiotics designing. J Biomol Struct Dyn. 22:1–16 doi: 10.1080/07391102.2018.1498805.
   Google Scholar
• Andersson JA, Sha J, Kirtley ML, Reyes E, Fitts EC, Dann SM, Chopra AK. 2017. Combating multidrug-resistant pathogens with host-directed nonantibiotic therapeutics. Antimicrob Agents Chemother. 62:pii: e01943–e01917.
   PubMed Web of Science ®Google Scholar
• Arivett BA, Fiester SE, Ohneck EJ, Penwell WF, Kaufman CM, Relich RF, Actis LA. 2015. Antimicrobial activity of Gallium Protoporphyrin IX against Acinetobacter baumannii strains displaying different antibiotic resistance phenotypes. Antimicrob Agents Chemother. 59:7657–7665.
   PubMed Web of Science ®Google Scholar
• Assis FV, Siqueira FL, Gonçalves IE, Lacerda RP, Nascimento RA, Araújo SG, Andrade JT, Herrera KMS, Lima LRS, Ferreira JMS. 2018. Antibacterial activity of Lamiaceae plant extracts in clinical isolates of multidrug resistant bacteria. An Acad Bras Ciênc. 90:1665–1670.
   PubMed Web of Science ®Google Scholar
• Aziz MA, Adnan M, Rahman H, Allah EF, Hashem A, Alqarawi AA. 2017. Antibacterial activities of medicinal plants against multidrug resistant urinary tract pathogens. Pak J Bot. 49:1185–1192.
   Web of Science ®Google Scholar
• Bajorath J. 2016. Computer-aided drug discovery. F1000 Res. 4:630.
   Google Scholar
• Bardbari AM, Arabestani MR, Karami M, Keramat F, Alikhani MY, Bagheri KP. 2017. Correlation between ability of biofilm formation with their responsible genes and MDR patterns in clinical an environmental Acinetobacter baumannii isolates. Microb Pathog. 108:122–128.
   PubMed Web of Science ®Google Scholar
• Beni Z, Dekany M, Kovacs B, Csupor-Loffler B, Zomborszki ZP, Kerekes E, Szekeres A, Urban E, Hohmann J, Vanyolos A. 2018. Bioactivity guided isolation of antimicrobial and antioxidant metabolites from the mushroom Tapinella atrotomentosa. Molecules. 23:pii:E1082.
   Web of Science ®Google Scholar
• Betts JW, Hornsey M, Wareham DW, Ragione RML. 2017. In vitro and in vivo activity of theaflavin–epicatechin combinations versus multidrug-resistant Acinetobacter baumannii. Infect Dis Ther. 6:435–442.
   PubMed Web of Science ®Google Scholar
• Betts JW, Wareham DW. 2014. Invitro activity of curcumin in combination with epigallocatechingallate (EGCG ) versus multidrug-resistant Acinetobacter baumannii. BMC Microbiol. 14:172.
   PubMed Web of Science ®Google Scholar
• Bhuiyan MS, Ellett F, Murray GL, Kostoulias X, Cerqueira GM, Schulze KE, Mahamad Maifiah MH, Li J, Creek DJ, Lieschke GJ, et al. 2016. Acinetobacter baumannii phenylacetic acid metabolism influences infection outcome through a direct effect on neutrophil chemotaxis. Proc Natl Acad Sci USA. 113:9599–9604.
   PubMed Web of Science ®Google Scholar
• Bielaszewska M, Aldick T, Bauwens A, Karch H. 2014. Hemolysin of enter- ohemorrhagic Escherichia coli: structure, transport, biological activity and putative role in virulence. Int J Med Microbiol. 304:521–529.
   PubMed Web of Science ®Google Scholar
• Blair JM, Richmond GE, Piddock LJ. 2014. Multidrug efflux pumps in gram-negative bacteria and their role in antibiotic resistance. Future Microbiol. 9:1165–1177.
   PubMed Web of Science ®Google Scholar
• Boyd CD, Smith TJ, El-Kirat-Chatel S, Newell PD, Dufrene YF, O’Toole GA. 2014. Structural features of the Pseudomonas fluorescens biofilm adhesin LapA required for LapG-dependent cleavage, biofilm formation, and cell surface localization. J Bacteriol. 196:2775–2788.
   PubMed Web of Science ®Google Scholar
• Bozovic M, Pirolli A, Ragno R. 2015. Mentha suaveolens Ehrh (Lamiaceae) essential oil and its main constituent piperitenone oxide: biological activities and chemistry. Molecules. 20:8605–8633.
   PubMed Web of Science ®Google Scholar
• Chan AP, Choi Y, Brinkac LM, Krishnakumar R, DePew J, Kim M, Hinkle MK, Lesho EP, Fouts DE. 2018. Multidrug resistant pathogens respond differently to the presence of co-pathogen, commensal, probiotic and host cells. Sci Rep. 8:8656.
   PubMed Web of Science ®Google Scholar
• Charretier Y, Diene SM, Baud D, Chatellier S, Santiago-Allexant E, van Belkum A, Guigon G, Schrenzel J. 2018. Colistin heteroresistance and the involvement of the PmrAB regulatory system in Acinetobacter baumannii. Antimicrob Agents Chemother. 62:pii:e00788–18.
   Web of Science ®Google Scholar
• Chin CY, Gregg KA, Napier BA, Ernst RK, Weiss DS. 2015. A PmrB-regulated deacetylase required for lipid A modification and polymyxin resistance in Acinetobacter baumannii. Antimicrob Agents Chemother. 59:7911–7914.
   PubMed Web of Science ®Google Scholar
• Chusri S, Na-Phatthalung P, Siriyong T, Paosen S, Voravuthikunchai SP. 2014. Holarrhena antidysenterica as a resistance modifying agent against Acinetobacter baumannii: its effects on bacterial outer membrane permeability and efflux pumps. Microbiol Res. 169:417–424.
   PubMedGoogle Scholar
• Cianciotto NP, White RC. 2017. Expanding role of type II secretion in bacterial pathogenesis and beyond. Infect Immun. 85:pii:e00014–17.
   Web of Science ®Google Scholar
• Costa TRD, Felisberto-Rodrigues C, Meir A, Prevost MS, Redzej A, Trokter M, Waksman G. 2015. Secretion systems in gram-negative bacteria: structural and mechanistic insights. Nat Rev Microbiol. 13:343–359.
   PubMed Web of Science ®Google Scholar
• Da Silva GJ, Domingues S. 2017. Interplay between colistin resistance, virulence and fitness in Acinetobacter baumannii. Antibiotics (Basel). 6:pii:E28.
   Web of Science ®Google Scholar
• Defraine V, Schuermans J, Grymonprez B, Govers SK, Aertsen A, Fauvart M, Michiels J, Lavigne R, Briers Y. 2016. Efficacy of artilysin Art -175 against resistant and persistent Acinetobacter baumannii. Antimicrob Agents Chemother. 60:3480–3488.
   PubMed Web of Science ®Google Scholar
• Di Domenico EG, Farulla I, Prignano G, Gallo MT, Vespaziani M, Cavallo I, Sperduti I, Pontone M, Bordignon V, Cilli L, et al. 2017. Biofilm is a major virulence determinant in bacterial colonization of chronic skin ulcers independently from the multidrug resistant phenotype. Int J Mol Sci. 18:1077.
   Web of Science ®Google Scholar
• Dubey KK, Kumar P, Labrou NE, Shukla P. 2017. Biotherapeutic potential and mechanisms of action of colchicine. Crit Rev Biotechnol. 37:1038–1047.
   PubMed Web of Science ®Google Scholar
• Dubey KK, Luke GA, Knox C, Kumar P, Pletschke BI, Singh PK, Shukla P. 2018. Vaccine and antibody production in plants: developments and computational tools. Brief Funct Genomics. 17:295–307.
   PubMed Web of Science ®Google Scholar
• Eftekhar F, Ashoori N, Yousefzadi M. 2017. In-vitro antimicrobial activity and chemical composition of Satureja khuzestanica Jamzad essential oils against multidrug-resistant Acinetobacter baumannii. Avicenna J Clin Microb Infect. 4:e45601.
   Google Scholar
• Fiester SE, Arivett BA, Schmidt RE, Beckett AC, Ticak T, Carrier MV, Ghosh R, Ohneck EJ, Metz ML, Sellin Jeffries MK, et al. 2016. Iron-regulated phospholipase C activity contributes to the cytolytic activity and virulence of Acinetobacter baumannii. PLoS One. 11:e0167068.
   PubMed Web of Science ®Google Scholar
• Flores-Diaz M, Monturiol-Gross L, Naylor C, Alape-Giron A, Flieger A. 2016. Bacterial sphingomyelinases and phospholipases as virulence factors. Microbiol Mol Biol Rev. 80:597–628.
   PubMed Web of Science ®Google Scholar
• Garnacho-Montero J, Timsit JF. 2019. Managing Acinetobacter baumannii infections. Curr Opin Infect Dis. 32:69–76.
   PubMed Web of Science ®Google Scholar
• Geisinger E, Isberg RR. 2015. Antibiotic modulation of capsular exopolysaccharide and virulence in Acinetobacter baumannii. PLoS Pathog. 11:e1004691.
   PubMed Web of Science ®Google Scholar
• Goyal M, Citu SN. 2018. In silico identification of novel drug targets in Acinetobacter baumannii by subtractive genomic approach. Asian J Pharm Clin Res. 11:230–236.
   Google Scholar
• Gupta SK, Shukla P. 2017. Sophisticated cloning, fermentation, and purification technologies for an enhanced therapeutic protein production: a review. Front Pharmacol. 8:419.
   PubMed Web of Science ®Google Scholar
• Gupta SK, Dangi AK, Smita M, Dwivedi S, Shukla P. 2019. Effectual bioprocess development for protein production. In: Shukla P, editor. Applied microbiology and bioengineering. Cambridge (MA): Academic Press; p. 203–227.
   Google Scholar
• Hacioglu M, Dosler S, Tan ASB, Otuk G. 2017. Antimicrobial activities of widely consumed herbal teas, alone or in combination with antibiotics: an in vitro study. Peer J. 5:e3467.
   PubMed Web of Science ®Google Scholar
• Ibrahim ME. 2019. Prevalence of Acinetobacter baumannii in Saudi Arabia: risk factors, antimicrobial resistance patterns and mechanisms of carbapenem resistance. Ann Clin Microbiol Antimicrob. 18:1.
   PubMed Web of Science ®Google Scholar
• Intorasoot A, Chornchoem P, Sookkhee S, Intorasoot S. 2017. Bactericidal activity of herbal volatile oil extracts against multidrug-resistant Acinetobacter baumannii. J Intercult Ethnopharmacol. 6:1–222.
   PubMedGoogle Scholar
• Iyer R, Moussa SH, Durand-Reville TF, Tommasi R, Miller A. 2018. Acinetobacter baumannii OmpA is a selective antibiotic permeant porin. ACS Infect Dis. 4:373–381.
   PubMed Web of Science ®Google Scholar
• Jamadagni PS, Pawar SD, Jamadagni SB, Chougule S, Gaidhani SN, Murthy SN. 2017. Review of Holarrhena antidysenterica (l.) wall. ex a. dc.: pharmacognostic, pharmacological, and toxicological perspective. Phcog Rev. 11:141–144.
   Google Scholar
• Jia W, Li C, Zhang H, Li G, Liu X, Wei J. 2015. Prevalence of genes of OXA-23 carbapenemase and AdeABC efflux pump associated with multidrug resistance of Acinetobacter baumannii isolates in the ICU of a comprehensive hospital of Northwestern China. Int J Environ Res Public Health. 12:10079–10092.
   PubMed Web of Science ®Google Scholar
• Johnson TL, Waack U, Smith S, Mobley H, Sandkvist M. 2016. Acinetobacter baumannii is dependent on the type II secretion system and its substrate LipA for lipid utilization and in vivo fitness. J Bacteriol. 198:711–719.
   Web of Science ®Google Scholar
• Kaur A, Sharma P, Capalash N. 2018. Curcumin alleviates persistence of Acinetobacter baumannii against colistin. Sci Rep. 8:11029.
   PubMed Web of Science ®Google Scholar
• Kaye KS, Pogue JM, Tran TB, Nation RL, Li J. 2016. agents of last resort: polymyxin resistance. Infect Dis Clin N Am. 30:391–414.
   PubMed Web of Science ®Google Scholar
• Kazi A, Chuah C, Majeed ABA, Leow CH, Lim BH, Leow CY. 2018. Current progress of immunoinformatics approach harnessed for cellular- and antibody-dependent vaccine design. Pathog Glob Health. 112:123–131.
   PubMed Web of Science ®Google Scholar
• Khafaji A, Samaree A. 2017. Design of synthetic antimicrobial peptides against resistant Acinetobacter baumannii using computational approach. Int J Pharm Sci Res. 8:2033–2039.
   Web of Science ®Google Scholar
• Khan I, Rahman H, Abd El-Salam NM, Tawab A, Hussain A, Khan TA, Khan UA, Qasim M, Adnan M, Azizullah A, et al. 2017. Punica granatum peel extracts: HPLC fractionation and LC MS analysis to quest compounds having activity against multidrug resistant bacteria. BMC Complement Altern Med. 17:247.
   PubMed Web of Science ®Google Scholar
• Kim UJ, Kim HK, An JH, Cho SK, Park KH, Jang HC. 2014. Update on the epidemiology, treatment and outcomes of carbapenem-resistant Acinetobacter infections. Chonnam Med J. 50:37–44.
   PubMedGoogle Scholar
• Kroger C, Kary SC, Schauer K, Cameron S. 2016. Genetic regulation of virulence and antibiotic resistance in Acinetobacter baumannii. Genes (Basel). 8:pii:E12.
   PubMed Web of Science ®Google Scholar
• Larsen JE, Lund O, Nielsen M. 2006. Improved method for predicting linear B-cell epitopes. Immunome Res. 2:2.
   PubMedGoogle Scholar
• Lee JH, Park KS, Karim AM, Lee CR, Lee SH. 2016. How to minimise antibiotic resistance. Lancet Infect Dis. 16:17–18.
   PubMedGoogle Scholar
• Lee C, Lee JH, Park M, Park KS, Bae KII, Kim YB, Cha C, Jeong BC, Lee SH. 2017. Biology of Acinetobacter baumannii: pathogenesis, antibiotic resistance mechanisms and prospective treatment options. Front Cell Infection Microbiol. 7:55.
   PubMed Web of Science ®Google Scholar
• Lenhard JR, Bulitta JB, Connell TD, King-Lyons N, Landersdorfer CB, Cheah SE, Thamlikitkul V, Shin BS, Rao G, Holden PN, et al. 2017. High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii. J Antimicrob Chemother. 72:153–165.
   PubMed Web of Science ®Google Scholar
• Lihua Q, Hao L, Chuanfu Z, Beibei L, Jie L, Ligui W, Xinying D, Xuelin L, Shaofu Q, Hongbin S. 2016. Relationship between antibiotic resistance, biofilm formation and biofilm-specific resistance in Acinetobacter baumannii. Front Microbiol. 7:483.
   PubMed Web of Science ®Google Scholar
• Liktor BE, Kovacs B, Urban E, Hohmann J, Ványolos A. 2016. Investigation of Hungarian mushrooms for antibacterial activity and synergistic effects with standard antibiotics against resistant bacterial strains. Lett Appl Microbiol. 62:437–443.
   PubMed Web of Science ®Google Scholar
• Liou ML, Soo PC, Ling SR, Kuo HY, Tang CY, Chang KC. 2014. The sensor kinase BfmS mediates virulence in Acinetobacter baumannii. J Microbiol Immunol Infect. 47:275–281.
   PubMedGoogle Scholar
• Liu X, Zhao M, Chen Y, Bian X, Li Y, Shi J, Zhang J. 2016. Synergistic killing by meropenem and colistin combination of carbapenem-resistant Acinetobacter baumannii isolates from Chinese patients in an in vitro pharmacokinetic/pharmacodynamic model. Int J Antimicrob Agents. 48:559–563.
   PubMed Web of Science ®Google Scholar
• Lopez M, Mayer C, Fernandez-García L, Blasco L, Muras A, Ruiz FM, Bou G, Otero A, Tomas M. 2017. Quorum sensing network in clinical strains of A. baumannii: AidA is a new quorum quenching enzyme. PLoS One. 12:e0174454.
   PubMed Web of Science ®Google Scholar
• Lopez-Rojas R, Garcia-Quintanilla M, Labrador-Herrera G, Pachon J, McConnell MJ. 2016. Impaired growth under iron-limiting conditions associated with the acquisition of colistin resistance in Acinetobacter baumannii. Int J Antimicrob Agents. 47:473–477.
   PubMed Web of Science ®Google Scholar
• Malathi K, Anbarasu A, Ramaiah S. 2017. Exploring the resistance mechanism of imipenem in carbapenem hydrolysing class D betalactamases OXA-143 and its variant OXA231 (D224A) expressing Acinetobacter baumannii: an in-silico approach. Comput Biol Chem. 67:1–8.
   PubMed Web of Science ®Google Scholar
• Manikkam R, Joseph J. 2016. In silico docking analysis of actinobacterial sideromycins with the alanine racemase enzyme of Acinetobacter baumanii. Int J Comput Biol. 5(2): 06–08.
   Google Scholar
• Matamouros S, Miller SIS. 2015. S. typhimurium strategies to resist killing by cationic antimicrobial peptides. Biochim Biophys Acta BBA Biomembr. 1848:3021–3025.
   Web of Science ®Google Scholar
• Meletis G. 2016. Carbapenem resistance: overview of the problem and future perspectives. Ther Adv Infect Dis. 3:15–21.
   PubMed Web of Science ®Google Scholar
• Menegucci TC, Albiero J, Migliorini LB, Alves JLB, Viana GF, Mazucheli J, Carrara-Marroni FE, Cardoso CL, Tognim MCB. 2016. Strategies for the treatment of polymyxin B-resistant Acinetobacter baumannii infections. Int J Antimicrob Agents. 47:380–385.
   PubMed Web of Science ®Google Scholar
• Mya T, Rolf L, Benjamin YW, Douglas RD, Chad WE, Vincent AF. 2016. Novel engineered peptides of a phage lysin as effective antimicrobials against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 60:2671–2679.
   PubMed Web of Science ®Google Scholar
• Nagarajan D, Nagarajan T, Roy N, Kulkarni O, Ravichandran S, Mishra M, Chakravortty D, Chandra N. 2018. Computational antimicrobial peptide design and evaluation against multidrug-resistant clinical isolates of bacteria. J Biol Chem. 293:3492–3509.
   PubMed Web of Science ®Google Scholar
• Nivaskumar M, Francetic O. 2014. Type II secretion system: a magic beanstalk or a protein escalator. Biochim Biophys Acta. 1843:1568–1577.
   PubMed Web of Science ®Google Scholar
• Noha M, Elhosseiny, Ahmed AS. 2018. Acinetobacter: an emerging pathogen with a versatile secretome. Emerg Microbes Infect. 7:33.
   PubMed Web of Science ®Google Scholar
• Novović K, Mihajlović S, Dinić M, Malešević M, Miljković M, Kojić M, Jovčić B. 2018. Acinetobacter spp. porin Omp33-36: Classification and transcriptional response to carbapenems and host cells. PLoS One. 13(8):e0201608. doi: 10.1371/journal.pone.0201608.
   PubMed Web of Science ®Google Scholar
• Perez A, Merino M, Rumbo-Feal S, Alvarez-Fraga L, Vallejo JA, Beceiro A, Ohneck EJ, Mateos J, Fernandez-Puente P, Actis LA, et al. 2017. The FhaB/FhaC two-partner secretion system is involved in adhesion of Acinetobacter baumannii AbH12O-A2 strain. Virulence. 8:959–974.
   PubMed Web of Science ®Google Scholar
• Pirovano W, Heringa J. 2010. Protein secondary structure prediction. Methods Mol Biol. 609:327–348.
   PubMedGoogle Scholar
• Ponomarenko J, Bui HH, Li W, Fusseder N, Bourne PE, Sette A, Peters B. 2008. ElliPro: a new structure-based tool for the prediction of antibody epitopes. BMC Bioinformatics. 9:514.
   PubMed Web of Science ®Google Scholar
• Pourhajibagher M, Hosseini N, Bahador A. 2018. Computational modeling and simulation of toxin-antitoxin system in Acinetobacter baumannii: HicB as a dynamic factor for therapeutic target. Der Pharm Chem. 10:99–105. ISSN 0975-413X.
   Google Scholar
• Rahbar MR, Rasooli I, Mousavi Gargari SL, Amani J, Fattahian Y. 2010. In silico analysis of antibody triggering biofilm associated protein in Acinetobacter baumannii. J Theor Biol. 266:275–290.
   PubMed Web of Science ®Google Scholar
• Rodriguez RL, Chang WL, Gutierrez D, Lavigne R, Martinez B, Rodriguez A. 2016. ‘Artilysation’ of endolysin lambdaSa2lys strongly improves its enzymatic and antibacterial activity against Streptococci. Sci Rep. 6:35382.
   PubMed Web of Science ®Google Scholar
• Rossi E, Longo F, Barbagallo M, Peano C, Consolandi C, Pietrelli A, Jaillon S, Garlanda C, Landini P. 2016. Glucose availability enhances lipopolysaccharide production and immunogenicity in the opportunistic pathogen Acinetobacter baumannii. Future Microbiol. 11:335–349.
   Web of Science ®Google Scholar
• Rumbo C, Tomas M, Fernandez ME, Soares NC, Carvajal M, Santillana E, Beceiro A, Romero A, Bou G. 2014. The Acinetobacter baumannii Omp33-36 porin is a virulence factor that induces apoptosis and modulates autophagy in human cells. Infect Immun. 82:4666–4680.
   Web of Science ®Google Scholar
• Russo TA, Manohar A, Beanan JM, Olson R, MacDonald U, Graham J, Umland TC. 2016. The response regulator BfmR is a potential drug target for Acinetobacter baumannii. mSphere. 1:pii: e00082–16.
   Web of Science ®Google Scholar
• Ryall KA, Tan AC. 2015. Systems biology approaches for advancing the discovery of effective drug combinations. J Cheminform. 7:7.
   PubMed Web of Science ®Google Scholar
• Saha S, Raghava GPS. 2004. BcePred: prediction of continuous B-cell epitopes in antigenic sequences using physico-chemical properties. Artif Immun Syst. 3239:197–204.
   Google Scholar
• Saleem M, Bhatti HN, Jilani MI, Hanif MA. 2015. Bioanalytical evaluation of Cinnamomum zeylanicum essential oil. Nat Prod Res. 29:1857–1859.
   PubMed Web of Science ®Google Scholar
• Saulnier P. 2014. Aromatic and terpenic compounds loaded in lipidic nano capsules: activity against multi-drug resistant Acinetobacter baumannii assessed invitro and in a murine model of sepsis. J Nanomed Nanotechnol. 5:206.
   Google Scholar
• Selasi GN. 2016. Differences in biofilm mass, expression of biofilm-associated genes, and resistance to desiccation between epidemic and sporadic clones of carbapenem-resistant Acinetobacter baumannii sequence type 191. PLoS One. 11:e0162576.
   PubMed Web of Science ®Google Scholar
• Shukla P. 2018. Futuristic protein engineering: developments and avenues. Curr Protein Pept Sci. 19:3–4.
   PubMed Web of Science ®Google Scholar
• Siriyong T, Chusri S, Srimanote P, Tipmanee V, Voravuthikunchai SP. 2016. Holarrhena antidysenterica extract and its steroidal alkaloid, conessine, as resistance-modifying agents against extensively drug-resistant Acinetobacter baumannii. Microb Drug Resis. 22:273–282.
   PubMed Web of Science ®Google Scholar
• Skalweit MJ, Li M. 2016. Bulgecin A as a b-lactam enhancer for carbapenem-resistant Pseudomonas aeruginosa and carbapenem-resistant Acinetobacter baumannii clinical isolates containing various resistance mechanisms. Drug Des Devel Ther. 10:3013–3020.
   PubMed Web of Science ®Google Scholar
• Skariyachan S, Manjunath M, Bachappanavar N. 2018. Screening of potential lead molecules against prioritised targets of multi-drug resistant-Acinetobacter baumannii – insights from molecular docking, molecular dynamic simulations and in vitro assays. J Biomol Struct Dyn. 37:1146–1169.
   PubMed Web of Science ®Google Scholar
• Solanki V, Tiwari V. 2018. Subtractive proteomics to identify novel drug targets and reverse vaccinology for the development of chimeric vaccine against Acinetobacter baumannii. Sci Rep. 8:9044.
   PubMed Web of Science ®Google Scholar
• Soojhawon I, Pattabiraman N, Tsang A, Roth AL, Kang E, Noble SM. 2017. Discovery of novel inhibitors of multidrug-resistant Acinetobacter baumannii. Bioorg Med Chem. 25:5477–5482.
   PubMedGoogle Scholar
• Stahl J, Bergmann H, Gottig S, Ebersberger I, Averhoff B. 2015. Acinetobacter baumannii virulence is mediated by the concerted action of three phospholipases D. PLoS One. 10:e0138360.
   PubMed Web of Science ®Google Scholar
• Sun N, Chan FY, Lu YJ, Neves MA, Lui HK, Wang Y. 2014. Rational design of berberine-based ftsZ inhibitors with broad-spectrum antibacterial activity. PLoS One. 9:e97514.
   PubMed Web of Science ®Google Scholar
• Sweredoski MJ, Baldi P. 2009. COBEpro: a novel system for predicting continuous B-cell epitopes. Protein Eng Des Sel. 22:113–120.
   PubMed Web of Science ®Google Scholar
• Thomas S, Holland IB, Schmitt L. 2014. The type 1 secretion pathway-the hemolysin system and beyond. Biochim Biophys Acta. 1843:1629–1641.
   Web of Science ®Google Scholar
• Thummeepak R, Kongthai P, Leungtongkam U, Sitthisak S. 2016. Distribution of virulence genes involved in biofilm formation in multi-drug resistant Acinetobacter baumannii clinical isolates. Int Microbiol. 19:121–129.
   PubMed Web of Science ®Google Scholar
• Tiwari V, Tiwari D, Patel V, Tiwari M. 2017. Effect of secondary metabolite of Actinidia deliciosa on the biofilm and extra-cellular matrix components of Acinetobacter baumannii. Microb Pathog. 110:345–351.
   PubMed Web of Science ®Google Scholar
• Tiwari V, Patel V, Tiwari M. 2017. In-silico screening and experimental validation reveal L-Adrenaline as antibiofilm molecule biofilm molecule against biofilm associated protein (Bap) producing Acinetobacter baumannii. Int J Biol Macromol. 107:1242–1252.
   PubMed Web of Science ®Google Scholar
• Tiwari M, Roy R, Tiwari V. 2016. Screening of herbal-based bioactive extract against carbapenem-resistant strain of Acinetobacter baumannii. Microb Drug Resist. 22:364–371.
   Web of Science ®Google Scholar
• Trimble MJ, Mlynar CP, Kola RM, Hancock REW. 2016. Polymyxin: alternative mechanisms of action and resistance. Cold Spring Harb Perspect Med. 6:pii:a025288.
   Web of Science ®Google Scholar
• Tsai C, Lin C, Hsu C, Chang C, Chang I, Lin L, Hung C, Wang J. 2018. Using the Chinese herb Scutellaria barbata against extensively drug-resistant infections: in vitro and in vivo Acinetobacter baumannii studies. BMC Complement Altern Med. 18:96.
   PubMed Web of Science ®Google Scholar
• Valle DL, Jr, Cabrera EC, Puzon JJ, Rivera WL. 2016. Antimicrobial activities of methanol, ethanol and supercritical CO2 extracts of Philippine pipebetle L on clinical isolates of Gram positive and Gram negative bacteria with transferable multiple drug resistance. PLoS One. 11:e0146349.
   PubMed Web of Science ®Google Scholar
• Verma P, Maurya P, Tiwari M, Tiwari V. 2017. In silico interaction studies suggest RND efflux pump mediates polymyxin resistance in Acinetobacter baumannii. J Biomol Struct Dyn. 37:95–103.
   PubMed Web of Science ®Google Scholar
• Vila-Farres X, Chu J, Ternei MA, Lemetre C, Park S, Perlin DS, Brady SF. 2018. An optimized synthetic-bioinformatic natural product antibiotic sterilizes multidrug-resistant Acinetobacter baumannii-infected wounds. mSphere. 3:pii: e00528–17.
   Web of Science ®Google Scholar
• Waack U, Johnson TL, Chedid K, Xi C, Simmons LA, Mobley HLT, Sandkvist M. 2017. The type II secretion system in Acinetobacter baumannii: its role in pathogenesis and translational implications. Front Cell Infect Microbiol. 7: 380. doi: 10.3389/fcimb.2017.00380
   PubMedGoogle Scholar
• Wood CR, Ohneck EJ, Edelmann E, Actis LA. 2018. A light-regulated type I pilus contributes to Acinetobacter baumannii biofilm, motility and virulence functions. Infect Immun. 86:pii:e00442–18.
   Web of Science ®Google Scholar
• Xia X. 2017. Bioinformatics and drug discovery. Curr Top Med Chem. 17:1709–1726.
   PubMedGoogle Scholar
• Yang Q, Schultz GS, Gibson DJ. 2017. A surfactant-based dressing to treat and prevent Acinetobacter baumannii biofilms. J Burn Care Res. 39:766–770.
   Web of Science ®Google Scholar
• Yoon EJ, Balloy V, Fiette L, Chignard M, Courvalin P, Grillot-Courvalin C. 2016. Contribution of the Ade resistance-nodulation-cell division-type efflux pumps to fitness and pathogenesis of Acinetobacter baumannii. mBio. 7:pii:e00697–16.
   Web of Science ®Google Scholar
• Zhang J, Xu LL, Gan D, Zhang X. 2018. In vitro study of bacteriophage AB3 endolysin LysAB3 activity against Acinetobacter baumannii biofilm and biofilm-bound Acinetobacter baumannii. Clin Lab. 64:1021–1030.
   PubMed Web of Science ®Google Scholar